BoYen Therapeutics, Inc.
TTPEX:789123.45
TWD
0.00
(0.00%)
BoYen Therapeutics, Inc.
TPEX:7891
(Taipei Exchange)
Recent
price
23.45
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BoYen Therapeutics, Inc. is a Taiwan-based clinical-stage biopharmaceutical company primarily engaged in the discovery, research, development, and commercialization of novel therapeutics for oncology, immunology, and inflammatory diseases. The company operates through integrated drug discovery platforms and translational medicine programs, offering a specialized pipeline of pharmaceutical candidates and biotherapeutic development capabilities. Its core products and services include investigational new drug candidates for solid tumors and hematological malignancies; targeted small-molecule inhibitors and kinase-modulating compounds; therapeutic monoclonal antibodies and biologic formulations; preclinical drug screening, pharmacological evaluation, and pharmacokinetic profiling services; clinical trial development and regulatory submission management; and technology licensing, intellectual property co-development, and pharmaceutical commercialization partnerships. The company targets global healthcare markets, serving biotechnology partners, multinational pharmaceutical corporations, and research institutions across Taiwan, the Asia-Pacific region, North America, and Europe. Headquartered in Taipei, Taiwan, BoYen Therapeutics was established to translate advanced biomedical research into clinical-stage pharmaceutical solutions. In recent developments, the company achieved registration and initiated trading on the Taipei Exchange Emerging Stock Board under the ticker symbol TPEX:7891, successfully completed strategic private funding rounds to support its expanding clinical trial programs, advanced key pipeline assets into regulated Phase I and Phase II clinical development, formed strategic cross-border research and licensing collaborations with international biopharmaceutical partners, and expanded its proprietary research and development infrastructure to accelerate candidate optimization and global regulatory filings.